PHASE-II TRIAL AND COST-ANALYSIS OF FAZARABINE IN ADVANCED NON-SMALL-CELL CARCINOMA OF THE LUNG - A SOUTHWEST-ONCOLOGY-GROUP STUDY

被引:33
作者
WILLIAMSON, SK
CROWLEY, JJ
LIVINGSTON, RB
PANELLA, TJ
GOODWIN, JW
机构
[1] SW ONCOL GRP,CTR STAT,SEATTLE,WA
[2] UNIV WASHINGTON,SEATTLE,WA
[3] THOMPSON CANC SURVIVAL CTR,KNOXVILLE,TN
[4] OZARKS REG CCOP,SPRINGFIELD,MO
关键词
FAZARABINE; NUCLEOSIDES; COST ANALYSIS; LUNG NEOPLASMS;
D O I
10.1007/BF02614223
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Fazarabine is a novel nucleoside with broad spectrum pre-clinical activity and was chosen for study in patients with incurable non-small cell carcinoma of the lung. The expenses associated with investigational treatment have been assumed to be more than what would occur with conventional therapy, however, data are limited. Methods: Twenty-three patients with metastatic non-small cell lung cancer were treated with fazarabine. Fazarabine was administered as a 72 hour continuous infusion at 2.0 mg/M(2)/hour. A cost analysis of treatment was calculated for patients treated in Springfield, MO. Results: There were no responses (0%, 95% confidence interval = 0-15%) and median survival was 8 months. An analysis of the cost of treatment in the 4 patients treated in Springfield, MO, was compared to the costs of treatment with 4 cycles of cisplatinum and etoposide. There were no significant differences in costs for patients treated with the investigational agent as compared with conventional chemotherapy. Conclusions: Fazarabine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung. Treatment with this agent in an investigational setting was no more expensive than treatment with conventional chemotherapy.
引用
收藏
页码:67 / 71
页数:5
相关论文
共 15 条
[1]  
DALAL M, 1986, CANCER RES, V46, P831
[2]  
DRISCOLL JS, 1985, INVEST NEW DRUG, V3, P331
[3]  
GLAZER RI, 1984, MOL PHARMACOL, V26, P381
[4]   SOUTHWEST-ONCOLOGY-GROUP STANDARD RESPONSE CRITERIA, END-POINT DEFINITIONS AND TOXICITY CRITERIA [J].
GREEN, S ;
WEISS, GR .
INVESTIGATIONAL NEW DRUGS, 1992, 10 (04) :239-253
[5]   PLANNED VERSUS ATTAINED DESIGN IN PHASE-II CLINICAL-TRIALS [J].
GREEN, SJ ;
DAHLBERG, S .
STATISTICS IN MEDICINE, 1992, 11 (07) :853-862
[6]  
GREM JL, 1987, INVEST NEW DRUG, V5, P315
[7]  
HOFFMAN PC, 1983, SEMIN ONCOL, V10, P111
[8]  
KLASTERSKY J, 1985, SEMIN ONCOL, V12, P38
[9]  
MINNA JD, 1985, CANCER PRINCIPLES PR, P507
[10]   CHEMOTHERAPY CAN PROLONG SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER - REPORT OF A CANADIAN MULTICENTER RANDOMIZED TRIAL [J].
RAPP, E ;
PATER, JL ;
WILLAN, A ;
CORMIER, Y ;
MURRAY, N ;
EVANS, WK ;
HODSON, DI ;
CLARK, DA ;
FELD, R ;
ARNOLD, AM ;
AYOUB, JI ;
WILSON, KS ;
LATREILLE, J ;
WIERZBICKI, RF ;
HILL, DP .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (04) :633-641